产品名称

AMG 208

产品货号

Axon 1916 CAS [1002304-34-8] MF C22H17N5O2MW 383.40 Purity: 99% Read COA for solubility Description Potent and selective inhibitor of c-MET receptor tyrosine kinase (RTK); AMG208 inhibits both ligand-dependent and ligand-independent c-MET activation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival References Certificates Categories Extra info B.K. Albrecht et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J. Med. Chem. 2008, 51, 2879-2882. A.A. Boezio et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 6307-6312. X. Liu et al. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol. Med. 2010, 16, 37-45. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology c-MET RTK class X; EC 2.7.10.1 Inhibitor of c-MET receptor tyrosine kinase (RTK) Chemical name 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methylphenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline Parent CAS No. [1002304-34-8] Order Size Unit Price Stock 10 mg €110.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

AMG 208

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 1916

CAS [1002304-34-8]

MF C22H17N5O2
MW 383.40

Purity: 99%
Read COA for solubility

AMG 208

Description

Potent and selective inhibitor of c-MET receptor tyrosine kinase (RTK); AMG208 inhibits both ligand-dependent and ligand-independent c-MET activation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival

B.K. Albrecht et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J. Med. Chem. 2008, 51, 2879-2882.

A.A. Boezio et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 6307-6312.

X. Liu et al. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol. Med. 2010, 16, 37-45.

Cell Signaling & Oncology c-MET RTK class X; EC 2.7.10.1

Inhibitor of c-MET receptor tyrosine kinase (RTK)

Chemical name

7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methylphenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline

Parent CAS No.

[1002304-34-8]

产品资料